context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The fair value of long-term debt was $ 36.7 billion and $ 34.9 billion at December 31, 2023 and 2022, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments. | text | 36.7 | monetaryItemType | text: <entity> 36.7 </entity> <entity type> monetaryItemType </entity type> <context> The fair value of long-term debt was $ 36.7 billion and $ 34.9 billion at December 31, 2023 and 2022, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments. </context> | us-gaap:DebtInstrumentFairValue |
The fair value of long-term debt was $ 36.7 billion and $ 34.9 billion at December 31, 2023 and 2022, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments. | text | 34.9 | monetaryItemType | text: <entity> 34.9 </entity> <entity type> monetaryItemType </entity type> <context> The fair value of long-term debt was $ 36.7 billion and $ 34.9 billion at December 31, 2023 and 2022, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments. </context> | us-gaap:DebtInstrumentFairValue |
In February 2024, we entered into a $ 10.0 billion 364-day senior unsecured delayed draw term loan facility to provide bridge financing for the planned acquisitions of Karuna and RayzeBio. This facility would be drawn only if these acquisitions close prior to our planned issuance of debt securities and, if drawn, would be repaid following the issuance of such securities. No amounts were outstanding as of February 13, 2024. | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> In February 2024, we entered into a $ 10.0 billion 364-day senior unsecured delayed draw term loan facility to provide bridge financing for the planned acquisitions of Karuna and RayzeBio. This facility would be drawn only if these acquisitions close prior to our planned issuance of debt securities and, if drawn, would be repaid following the issuance of such securities. No amounts were outstanding as of February 13, 2024. </context> | us-gaap:DebtInstrumentFaceAmount |
In February 2024, we entered into a $ 10.0 billion 364-day senior unsecured delayed draw term loan facility to provide bridge financing for the planned acquisitions of Karuna and RayzeBio. This facility would be drawn only if these acquisitions close prior to our planned issuance of debt securities and, if drawn, would be repaid following the issuance of such securities. No amounts were outstanding as of February 13, 2024. | text | No | monetaryItemType | text: <entity> No </entity> <entity type> monetaryItemType </entity type> <context> In February 2024, we entered into a $ 10.0 billion 364-day senior unsecured delayed draw term loan facility to provide bridge financing for the planned acquisitions of Karuna and RayzeBio. This facility would be drawn only if these acquisitions close prior to our planned issuance of debt securities and, if drawn, would be repaid following the issuance of such securities. No amounts were outstanding as of February 13, 2024. </context> | us-gaap:ShortTermBorrowings |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. | text | 4.5 | monetaryItemType | text: <entity> 4.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. </context> | us-gaap:DebtInstrumentCarryingAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. | text | 6.0 | monetaryItemType | text: <entity> 6.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. </context> | us-gaap:DebtInstrumentCarryingAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. | text | 5.9 | monetaryItemType | text: <entity> 5.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. </context> | us-gaap:ProceedsFromDebtNetOfIssuanceCosts |
In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 6.0 | monetaryItemType | text: <entity> 6.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:ExtinguishmentOfDebtAmount |
In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 6.6 | monetaryItemType | text: <entity> 6.6 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:PaymentsOfDebtExtinguishmentCosts |
In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 266 | monetaryItemType | text: <entity> 266 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:GainsLossesOnExtinguishmentOfDebt |
In 2021, BMS purchased aggregate principal amount of $ 3.5 billion of certain of its debt securities for approximately $ 4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, BMS purchased aggregate principal amount of $ 3.5 billion of certain of its debt securities for approximately $ 4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:ExtinguishmentOfDebtAmount |
In 2021, BMS purchased aggregate principal amount of $ 3.5 billion of certain of its debt securities for approximately $ 4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 4.0 | monetaryItemType | text: <entity> 4.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, BMS purchased aggregate principal amount of $ 3.5 billion of certain of its debt securities for approximately $ 4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:PaymentsOfDebtExtinguishmentCosts |
In 2021, BMS purchased aggregate principal amount of $ 3.5 billion of certain of its debt securities for approximately $ 4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 281 | monetaryItemType | text: <entity> 281 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, BMS purchased aggregate principal amount of $ 3.5 billion of certain of its debt securities for approximately $ 4.0 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 281 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:GainsLossesOnExtinguishmentOfDebt |
Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. </context> | us-gaap:RepaymentsOfNotesPayable |
Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. | text | 4.8 | monetaryItemType | text: <entity> 4.8 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. </context> | us-gaap:RepaymentsOfNotesPayable |
Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. </context> | us-gaap:RepaymentsOfNotesPayable |
Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. </context> | us-gaap:InterestPaidNet |
Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. </context> | us-gaap:InterestPaidNet |
Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> Repayment of notes at maturity aggregated $ 3.9 billion in 2023, $ 4.8 billion in 2022 and $ 2.0 billion in 2021. Interest payments were $ 1.2 billion in 2023, $ 1.4 billion in 2022 and $ 1.5 billion in 2021. </context> | us-gaap:InterestPaidNet |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:InterestExpenseLongTermDebt |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:InterestExpenseLongTermDebt |
The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> The aggregate maturities of long-term debt for each of the next five years are as follows: $ 2.9 billion in 2024; $ 1.9 billion in 2025; $ 2.0 billion in 2026; $ 2.0 billion in 2027; and $ 1.5 billion in 2028. Interest payments related to long-term debt for each of the next five years are as follows: $ 1.4 billion in 2024; $ 1.4 billion in 2025; $ 1.3 billion in 2026; $ 1.3 billion in 2027; and $ 1.2 billion in 2028. </context> | us-gaap:InterestExpenseLongTermDebt |
As of December 31, 2023, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2028, which is extendable annually by one year with the consent of the lenders. In January 2024, we extended the credit facility to January 2029. Additionally, in February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility. The facilities provide for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for BMS’ commercial paper borrowings. No borrowings were outstanding under any revolving credit facility as of December 31, 2023 or 2022. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2028, which is extendable annually by one year with the consent of the lenders. In January 2024, we extended the credit facility to January 2029. Additionally, in February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility. The facilities provide for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for BMS’ commercial paper borrowings. No borrowings were outstanding under any revolving credit facility as of December 31, 2023 or 2022. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
As of December 31, 2023, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2028, which is extendable annually by one year with the consent of the lenders. In January 2024, we extended the credit facility to January 2029. Additionally, in February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility. The facilities provide for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for BMS’ commercial paper borrowings. No borrowings were outstanding under any revolving credit facility as of December 31, 2023 or 2022. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, BMS had a five-year $ 5.0 billion revolving credit facility expiring in January 2028, which is extendable annually by one year with the consent of the lenders. In January 2024, we extended the credit facility to January 2029. Additionally, in February 2024, we entered into a $ 2.0 billion 364-day revolving credit facility. The facilities provide for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for BMS’ commercial paper borrowings. No borrowings were outstanding under any revolving credit facility as of December 31, 2023 or 2022. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
(a) Includes provision for expected credit loss of $ 14 million in 2023, $ 7 million in 2022 and $ 4 million in 2021. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes provision for expected credit loss of $ 14 million in 2023, $ 7 million in 2022 and $ 4 million in 2021. </context> | us-gaap:ProvisionForDoubtfulAccounts |
(a) Includes provision for expected credit loss of $ 14 million in 2023, $ 7 million in 2022 and $ 4 million in 2021. | text | 7 | monetaryItemType | text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes provision for expected credit loss of $ 14 million in 2023, $ 7 million in 2022 and $ 4 million in 2021. </context> | us-gaap:ProvisionForDoubtfulAccounts |
(a) Includes provision for expected credit loss of $ 14 million in 2023, $ 7 million in 2022 and $ 4 million in 2021. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes provision for expected credit loss of $ 14 million in 2023, $ 7 million in 2022 and $ 4 million in 2021. </context> | us-gaap:ProvisionForDoubtfulAccounts |
Total inventories include fair value adjustments resulting from the Celgene acquisition of approximately $ 84 million as of December 31, 2022. | text | 84 | monetaryItemType | text: <entity> 84 </entity> <entity type> monetaryItemType </entity type> <context> Total inventories include fair value adjustments resulting from the Celgene acquisition of approximately $ 84 million as of December 31, 2022. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory |
Depreciation expense was $ 611 million in 2023, $ 587 million in 2022 and $ 559 million in 2021. | text | 611 | monetaryItemType | text: <entity> 611 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 611 million in 2023, $ 587 million in 2022 and $ 559 million in 2021. </context> | us-gaap:Depreciation |
Depreciation expense was $ 611 million in 2023, $ 587 million in 2022 and $ 559 million in 2021. | text | 587 | monetaryItemType | text: <entity> 587 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 611 million in 2023, $ 587 million in 2022 and $ 559 million in 2021. </context> | us-gaap:Depreciation |
Depreciation expense was $ 611 million in 2023, $ 587 million in 2022 and $ 559 million in 2021. | text | 559 | monetaryItemType | text: <entity> 559 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 611 million in 2023, $ 587 million in 2022 and $ 559 million in 2021. </context> | us-gaap:Depreciation |
Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. | text | 389 | monetaryItemType | text: <entity> 389 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. </context> | us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability |
Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. | text | 85 | monetaryItemType | text: <entity> 85 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. </context> | us-gaap:OperatingLeaseImpairmentLoss |
Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. | text | 195 | monetaryItemType | text: <entity> 195 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. </context> | us-gaap:OperatingLeasePayments |
Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. | text | 203 | monetaryItemType | text: <entity> 203 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. </context> | us-gaap:OperatingLeasePayments |
Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. | text | 189 | monetaryItemType | text: <entity> 189 </entity> <entity type> monetaryItemType </entity type> <context> Right-of-use assets obtained in exchange for new operating lease obligations were $ 389 million in 2023. Right-of-use assets impairment charge was $ 85 million in 2023. Cash paid for amounts included in the measurement of operating lease liabilities was $ 195 million in 2023, $ 203 million in 2022 and $ 189 million in 2021. </context> | us-gaap:OperatingLeasePayments |
In November 2023, $ 2.8 billion of IPRD, previously allocated to repotrectinib ( | text | 2.8 | monetaryItemType | text: <entity> 2.8 </entity> <entity type> monetaryItemType </entity type> <context> In November 2023, $ 2.8 billion of IPRD, previously allocated to repotrectinib ( </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets |
In December 2023, BMS agreed to pay $ 400 million to the former shareholders of Impact Biomedicines to extinguish all remaining contingent milestone obligations, which was recorded to Acquired marketed product rights for | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> In December 2023, BMS agreed to pay $ 400 million to the former shareholders of Impact Biomedicines to extinguish all remaining contingent milestone obligations, which was recorded to Acquired marketed product rights for </context> | us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities |
in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. | text | 511 | monetaryItemType | text: <entity> 511 </entity> <entity type> monetaryItemType </entity type> <context> in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. </context> | us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease |
in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> in the amount of $ 511 million (after establishing the applicable deferred tax liability). The $ 400 million was paid in January 2024. </context> | us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 9.2 | monetaryItemType | text: <entity> 9.2 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 9.7 | monetaryItemType | text: <entity> 9.7 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 10.2 | monetaryItemType | text: <entity> 10.2 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 8.7 | monetaryItemType | text: <entity> 8.7 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 3.2 | monetaryItemType | text: <entity> 3.2 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 1.6 | monetaryItemType | text: <entity> 1.6 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour |
Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. | text | 1.6 | monetaryItemType | text: <entity> 1.6 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense of Other intangible assets was $ 9.2 billion in 2023, $ 9.7 billion in 2022 and $ 10.2 billion in 2021. Future annual amortization expense of Other intangible assets is expected to be approximately $ 8.7 billion in 2024, $ 3.2 billion in 2025, $ 1.7 billion in 2026, $ 1.6 billion in 2027 and $ 1.6 billion in 2028. </context> | us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive |
Other intangible asset impairment charges were $ 136 million in 2023, $ 101 million in 2022 and $ 1.2 billion in 2021. | text | 136 | monetaryItemType | text: <entity> 136 </entity> <entity type> monetaryItemType </entity type> <context> Other intangible asset impairment charges were $ 136 million in 2023, $ 101 million in 2022 and $ 1.2 billion in 2021. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
Other intangible asset impairment charges were $ 136 million in 2023, $ 101 million in 2022 and $ 1.2 billion in 2021. | text | 101 | monetaryItemType | text: <entity> 101 </entity> <entity type> monetaryItemType </entity type> <context> Other intangible asset impairment charges were $ 136 million in 2023, $ 101 million in 2022 and $ 1.2 billion in 2021. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
Other intangible asset impairment charges were $ 136 million in 2023, $ 101 million in 2022 and $ 1.2 billion in 2021. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> Other intangible asset impairment charges were $ 136 million in 2023, $ 101 million in 2022 and $ 1.2 billion in 2021. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
In 2021, a $ 610 million IPRD impairment charge for an investigational compound was recorded in Research and development expense primarily resulting from changes in clinical timelines, expected launch dates and competitive landscape. The compound is being studied as a potential treatment for hematologic diseases and was acquired in the acquisition of Celgene. The charge represented a partial write-down of its carrying value based on the estimated fair value determined using discounted cash flow projections. | text | 610 | monetaryItemType | text: <entity> 610 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, a $ 610 million IPRD impairment charge for an investigational compound was recorded in Research and development expense primarily resulting from changes in clinical timelines, expected launch dates and competitive landscape. The compound is being studied as a potential treatment for hematologic diseases and was acquired in the acquisition of Celgene. The charge represented a partial write-down of its carrying value based on the estimated fair value determined using discounted cash flow projections. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
In 2021, a $ 230 million IPRD impairment charge was recorded in Research and development expense following a decision to discontinue development of an investigational compound in connection with the prioritization of pipeline opportunities. The compound was being studied as a potential treatment for fibrotic diseases and was acquired in the acquisition of Celgene. The charge represented a full write-down based on the estimated fair value determined using discounted cash flow projections. | text | 230 | monetaryItemType | text: <entity> 230 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, a $ 230 million IPRD impairment charge was recorded in Research and development expense following a decision to discontinue development of an investigational compound in connection with the prioritization of pipeline opportunities. The compound was being studied as a potential treatment for fibrotic diseases and was acquired in the acquisition of Celgene. The charge represented a full write-down based on the estimated fair value determined using discounted cash flow projections. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
EU regulatory approval milestones of $ 300 million were achieved resulting in a $ 385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $ 315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections. | text | 300 | monetaryItemType | text: <entity> 300 </entity> <entity type> monetaryItemType </entity type> <context> EU regulatory approval milestones of $ 300 million were achieved resulting in a $ 385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $ 315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections. </context> | us-gaap:PaymentsToAcquireIntangibleAssets |
EU regulatory approval milestones of $ 300 million were achieved resulting in a $ 385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $ 315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections. | text | 385 | monetaryItemType | text: <entity> 385 </entity> <entity type> monetaryItemType </entity type> <context> EU regulatory approval milestones of $ 300 million were achieved resulting in a $ 385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $ 315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections. </context> | us-gaap:FiniteLivedIntangibleAssetsNet |
EU regulatory approval milestones of $ 300 million were achieved resulting in a $ 385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $ 315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections. | text | 315 | monetaryItemType | text: <entity> 315 </entity> <entity type> monetaryItemType </entity type> <context> EU regulatory approval milestones of $ 300 million were achieved resulting in a $ 385 million increase to the acquired marketed product rights intangible asset, after establishing the applicable deferred tax liability. An impairment charge of $ 315 million was recognized in Cost of products sold as the carrying value of this asset exceeded the projected undiscounted cash flows of the asset. The charge was equal to the excess of the asset's carrying value over its estimated fair value using discounted cash flow projections. </context> | us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill |
(a) Cash dividends declared per common share were $ 2.31 in 2023, $ 2.19 in 2022 and $ 2.01 in 2021. | text | 2.31 | perShareItemType | text: <entity> 2.31 </entity> <entity type> perShareItemType </entity type> <context> (a) Cash dividends declared per common share were $ 2.31 in 2023, $ 2.19 in 2022 and $ 2.01 in 2021. </context> | us-gaap:CommonStockDividendsPerShareDeclared |
(a) Cash dividends declared per common share were $ 2.31 in 2023, $ 2.19 in 2022 and $ 2.01 in 2021. | text | 2.19 | perShareItemType | text: <entity> 2.19 </entity> <entity type> perShareItemType </entity type> <context> (a) Cash dividends declared per common share were $ 2.31 in 2023, $ 2.19 in 2022 and $ 2.01 in 2021. </context> | us-gaap:CommonStockDividendsPerShareDeclared |
(a) Cash dividends declared per common share were $ 2.31 in 2023, $ 2.19 in 2022 and $ 2.01 in 2021. | text | 2.01 | perShareItemType | text: <entity> 2.01 </entity> <entity type> perShareItemType </entity type> <context> (a) Cash dividends declared per common share were $ 2.31 in 2023, $ 2.19 in 2022 and $ 2.01 in 2021. </context> | us-gaap:CommonStockDividendsPerShareDeclared |
BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares, effected in the open market or through privately negotiated transactions in compliance with Rule 10b-18 under the Exchange Act, including through Rule 10b5-1 trading plans. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method and are generally funded by cash on hand. In December 2023, the Board of Directors approved an increase of $ 3.0 billion to the share repurchase authorization for BMS's common stock. The remaining share repurchase capacity under the BMS share repurchase program was $ 5.0 billion as of December 31, 2023. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares, effected in the open market or through privately negotiated transactions in compliance with Rule 10b-18 under the Exchange Act, including through Rule 10b5-1 trading plans. The share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method and are generally funded by cash on hand. In December 2023, the Board of Directors approved an increase of $ 3.0 billion to the share repurchase authorization for BMS's common stock. The remaining share repurchase capacity under the BMS share repurchase program was $ 5.0 billion as of December 31, 2023. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
In 2021, BMS repurchased approximately 102 million shares of common stock for $ 6.2 billion. | text | 102 | sharesItemType | text: <entity> 102 </entity> <entity type> sharesItemType </entity type> <context> In 2021, BMS repurchased approximately 102 million shares of common stock for $ 6.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2021, BMS repurchased approximately 102 million shares of common stock for $ 6.2 billion. | text | 6.2 | monetaryItemType | text: <entity> 6.2 </entity> <entity type> monetaryItemType </entity type> <context> In 2021, BMS repurchased approximately 102 million shares of common stock for $ 6.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 69 | sharesItemType | text: <entity> 69 </entity> <entity type> sharesItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 40 | sharesItemType | text: <entity> 40 </entity> <entity type> sharesItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS entered into ASR agreements and repurchased 69 million shares of common stock for $ 5.0 billion. In addition, as part of its share repurchase program, BMS repurchased 40 million shares of its common stock for $ 3.0 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 70 | sharesItemType | text: <entity> 70 </entity> <entity type> sharesItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 4.0 | monetaryItemType | text: <entity> 4.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 17 | sharesItemType | text: <entity> 17 </entity> <entity type> sharesItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodShares |
In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS entered into ASR agreements and repurchased 70 million shares of common stock for $ 4.0 billion. In addition, as part of its share repurchase program, BMS repurchased 17 million shares of its common stock for $ 1.2 billion. </context> | us-gaap:StockRepurchasedDuringPeriodValue |
(a) Included in foreign currency are net investment hedges gains of $ 144 million and $ 125 million as of December 31, 2023 and December 31, 2022, respectively. | text | 144 | monetaryItemType | text: <entity> 144 </entity> <entity type> monetaryItemType </entity type> <context> (a) Included in foreign currency are net investment hedges gains of $ 144 million and $ 125 million as of December 31, 2023 and December 31, 2022, respectively. </context> | us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax |
(a) Included in foreign currency are net investment hedges gains of $ 144 million and $ 125 million as of December 31, 2023 and December 31, 2022, respectively. | text | 125 | monetaryItemType | text: <entity> 125 </entity> <entity type> monetaryItemType </entity type> <context> (a) Included in foreign currency are net investment hedges gains of $ 144 million and $ 125 million as of December 31, 2023 and December 31, 2022, respectively. </context> | us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax |
The net periodic benefit cost of defined benefit pension plans was $ 11 million, $ 27 million, and $ 28 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> The net periodic benefit cost of defined benefit pension plans was $ 11 million, $ 27 million, and $ 28 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The net periodic benefit cost of defined benefit pension plans was $ 11 million, $ 27 million, and $ 28 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 27 | monetaryItemType | text: <entity> 27 </entity> <entity type> monetaryItemType </entity type> <context> The net periodic benefit cost of defined benefit pension plans was $ 11 million, $ 27 million, and $ 28 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The net periodic benefit cost of defined benefit pension plans was $ 11 million, $ 27 million, and $ 28 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 28 | monetaryItemType | text: <entity> 28 </entity> <entity type> monetaryItemType </entity type> <context> The net periodic benefit cost of defined benefit pension plans was $ 11 million, $ 27 million, and $ 28 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The accumulated benefit obligation for defined benefit pension plans was $ 2.2 billion and $ 2.0 billion at December 31, 2023 and 2022, respectively. | text | 2.2 | monetaryItemType | text: <entity> 2.2 </entity> <entity type> monetaryItemType </entity type> <context> The accumulated benefit obligation for defined benefit pension plans was $ 2.2 billion and $ 2.0 billion at December 31, 2023 and 2022, respectively. </context> | us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation |
The accumulated benefit obligation for defined benefit pension plans was $ 2.2 billion and $ 2.0 billion at December 31, 2023 and 2022, respectively. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The accumulated benefit obligation for defined benefit pension plans was $ 2.2 billion and $ 2.0 billion at December 31, 2023 and 2022, respectively. </context> | us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. | text | 183 | monetaryItemType | text: <entity> 183 </entity> <entity type> monetaryItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. </context> | us-gaap:DefinedBenefitPlanBenefitObligation |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. | text | 187 | monetaryItemType | text: <entity> 187 </entity> <entity type> monetaryItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. </context> | us-gaap:DefinedBenefitPlanBenefitObligation |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. | text | 4.8 | percentItemType | text: <entity> 4.8 </entity> <entity type> percentItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. </context> | us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate |
Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. | text | 5.0 | percentItemType | text: <entity> 5.0 </entity> <entity type> percentItemType </entity type> <context> Comprehensive medical and group life benefits are provided for substantially all BMS U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The medical plan is contributory. Contributions are adjusted periodically and vary by date of retirement. The life insurance plan is noncontributory. Postretirement benefit plan obligations were $ 183 million and $ 187 million at December 31, 2023 and 2022, respectively. The weighted-average discount rate used to determine benefit obligations was 4.8 % and 5.0 % at December 31, 2023 and 2022, respectively. The net periodic benefit credits were not material. </context> | us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate |
The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2023 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 63 %) and other investments ( 16 %). | text | 21 | percentItemType | text: <entity> 21 </entity> <entity type> percentItemType </entity type> <context> The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2023 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 63 %) and other investments ( 16 %). </context> | us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations |
The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2023 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 63 %) and other investments ( 16 %). | text | 63 | percentItemType | text: <entity> 63 </entity> <entity type> percentItemType </entity type> <context> The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2023 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 63 %) and other investments ( 16 %). </context> | us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations |
The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2023 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 63 %) and other investments ( 16 %). | text | 16 | percentItemType | text: <entity> 16 </entity> <entity type> percentItemType </entity type> <context> The investment strategy is to maximize return while maintaining an appropriate level of risk to provide sufficient liquidity for benefit obligations and plan expenses. Individual plan investment allocations are determined by local fiduciary committees and the composition of total assets for all pension plans at December 31, 2023 was broadly characterized as an allocation between equity securities ( 21 %), debt securities ( 63 %) and other investments ( 16 %). </context> | us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations |
The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 380 million in 2023, $ 360 million in 2022 and $ 350 million in 2021. | text | 380 | monetaryItemType | text: <entity> 380 </entity> <entity type> monetaryItemType </entity type> <context> The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 380 million in 2023, $ 360 million in 2022 and $ 350 million in 2021. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 380 million in 2023, $ 360 million in 2022 and $ 350 million in 2021. | text | 360 | monetaryItemType | text: <entity> 360 </entity> <entity type> monetaryItemType </entity type> <context> The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 380 million in 2023, $ 360 million in 2022 and $ 350 million in 2021. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 380 million in 2023, $ 360 million in 2022 and $ 350 million in 2021. | text | 350 | monetaryItemType | text: <entity> 350 </entity> <entity type> monetaryItemType </entity type> <context> The principal defined contribution plan is the Bristol-Myers Squibb Savings and Investment Program. The contributions are based on employee contributions and the level of Company match. The U.S. defined contribution plan expense was approximately $ 380 million in 2023, $ 360 million in 2022 and $ 350 million in 2021. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2023, 70 million shares were available for award and 40 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. | text | 85 | sharesItemType | text: <entity> 85 </entity> <entity type> sharesItemType </entity type> <context> The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2023, 70 million shares were available for award and 40 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2023, 70 million shares were available for award and 40 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. | text | 70 | sharesItemType | text: <entity> 70 </entity> <entity type> sharesItemType </entity type> <context> The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2023, 70 million shares were available for award and 40 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2023, 70 million shares were available for award and 40 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. | text | 40 | sharesItemType | text: <entity> 40 </entity> <entity type> sharesItemType </entity type> <context> The 2021 Plan provides for 85 million shares to be authorized for grants plus shares recaptured upon forfeitures or other terminations of awards under our previous equity awards plans, subject to adjustments in accordance with the terms of the 2021 Plan. As of December 31, 2023, 70 million shares were available for award and 40 million equity awards were outstanding (stock options, RSUs, MSUs and PSUs). Shares generally are issued from treasury stock to satisfy BMS’s obligations under the 2021 Plan and our prior equity award plans. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
(a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $ 19 million in 2023, $ 74 million in 2022 and $ 38 million in 2021. | text | 19 | monetaryItemType | text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> (a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $ 19 million in 2023, $ 74 million in 2022 and $ 38 million in 2021. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
(a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $ 19 million in 2023, $ 74 million in 2022 and $ 38 million in 2021. | text | 74 | monetaryItemType | text: <entity> 74 </entity> <entity type> monetaryItemType </entity type> <context> (a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $ 19 million in 2023, $ 74 million in 2022 and $ 38 million in 2021. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
(a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $ 19 million in 2023, $ 74 million in 2022 and $ 38 million in 2021. | text | 38 | monetaryItemType | text: <entity> 38 </entity> <entity type> monetaryItemType </entity type> <context> (a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $ 19 million in 2023, $ 74 million in 2022 and $ 38 million in 2021. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions |
The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the closing stock price of $ 51.31 on December 29, 2023, which was the last trading day of 2023. | text | 51.31 | perShareItemType | text: <entity> 51.31 </entity> <entity type> perShareItemType </entity type> <context> The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the closing stock price of $ 51.31 on December 29, 2023, which was the last trading day of 2023. </context> | us-gaap:SharePrice |
Sanofi was notified that, in August 2007, GenRx Proprietary Limited ("GenRx") obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex ("GenRx-Apotex"). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi's Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi's injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia ("Full Court") appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($ 307 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded | text | 449 | monetaryItemType | text: <entity> 449 </entity> <entity type> monetaryItemType </entity type> <context> Sanofi was notified that, in August 2007, GenRx Proprietary Limited ("GenRx") obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex ("GenRx-Apotex"). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi's Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi's injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia ("Full Court") appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($ 307 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded </context> | us-gaap:LossContingencyDamagesPaidValue |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.